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Abstract
High plasma osteoprotegerin (OPG) and asymmetric dimethylarginine (ADMA) and low homoarginine (hArg) predict 
adverse renal and cardiovascular (CV) outcomes. In patients with chronic kidney disease and stable coronary artery disease, 
plasma OPG correlated with hArg (r = − 0.37, P = 0.03) and the hArg/ADMA molar ratio (r = − 0.46, P = 0.009), which 
was maintained upon adjustment for renal function. Elevated OPG levels and decreased hArg/ADMA ratios independently 
predicted 4-year composite CV and renal endpoints (CV death or progression to dialysis). Thus, high OPG and low hArg/
ADMA ratio, albeit interrelated, appear to independently contribute to adverse clinical outcome.
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Abbreviations
ADMA  Asymmetric dimethylarginine
AGAT  l-Arginine:glycine amidinotransferase
CAD  Coronary artery disease
CKD  Chronic kidney disease
CV  Cardiovascular
∆eGFR  eGFR change
eGFR  Estimated glomerular filtration rate
hArg  l-Homoarginine
NO  Nitric oxide
NOS  Nitric oxide synthase
OPG  Osteoprotegerin
Introduction
Osteoprotegerin (OPG) is expressed by osteoblasts, 
cytokine-activated endothelia, vascular myocytes and mac-
rophages and predicts adverse cardiovascular (CV) outcome 
in the general population (Kiechl et al. 2004; Semb et al. 
2009; Lieb et al. 2010; Tschiderer et al. 2017) and in various 
clinical settings (Tschiderer et al. 2018), including patients 
with chronic kidney disease (CKD) (Mesquita et al. 2009; 
Lewis et al. 2015; Kuźniewski et al. 2016; Yilmaz et al. 
2016), stable coronary artery disease (CAD) (Bjerre et al. 
2014) and acute coronary syndromes (Røysland et al. 2012). 
Elevated OPG levels are also associated with future rapid 
renal function decline in elderly women (Lewis et al. 2014) 
and progression to end-stage renal-disease in type 1 diabetes 
mellitus (Jorsal et al. 2008). OPG affects numerous intracel-
lular pathways that modulate activation and propensity to 
apoptosis (Venuraju et al. 2010).
In subjects with CAD (Morisawa et al. 2015) and essen-
tial hypertension (Tsioufis et al. 2011), OPG correlated 
positively with asymmetric dimethylarginine (ADMA), 
a recognized predictor of CV risk (Böger et al. 2009) and 
CKD progression (Fliser et al. 2005; Ravani et al. 2005). 
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ADMA originates from the proteolysis of proteins methyl-
ated on Arg residues by protein arginine methyltransferase 
1 (PRMT1; EC 2.1.1.125). hArg is primarily of renal origin 
and is biosynthesized by l-arginine:glycine amidinotrans-
ferase (AGAT; EC 2.1.4.1). To the best of our knowledge, no 
studies have dealt with relations of OPG and l-homoarginine 
(hArg), an emerging risk factor in the renal and CV systems 
(März et al. 2010; Atzler et al. 2013, 2014; Choe et al. 2013; 
Drechsler et al. 2013; Kleber et al. 2013; Ravani et al. 2013; 
Pilz et al. 2014; Frenay et al. 2015; Kayacelebi et al. 2017; 
Zinellu et al. 2018).
Associations of CV mortality risk with high OPG (Lewis 
et al. 2015) or low hArg (Tomaschitz et al. 2014) concentra-
tions are considerably stronger in subjects with an estimated 
GFR (eGFR) below 60 mL/min/1.73 m2. We, therefore, 
hypothesized that the kidneys may play a major role both 
in the homeostasis and modulation of biological effects of 
hArg and OPG in CKD patients with CAD. The primary 
aim of the present study was to test for mutual associations 
between OPG, hArg and ADMA in plasma of patients with 
CKD and CAD. We also tested a potential prognostic value 
of OPG with regard to 1-year renal function decline and 




Forty men with CKD were recruited from non-smoking 
patients admitted to the Second Department of Cardiol-
ogy of Jagiellonian University Medical College for elective 
coronary angiography for stable CAD (Table 1). All CKD 
subjects were free of heart failure, left ventricular systolic 
dysfunction (ejection fraction ≥ 50% by echocardiography), 
clinical instability or coexistent diseases except for well-
controlled type 2 diabetes mellitus or hypertension. Patients 
Table 1  Patients’ characteristics and plasma concentrations of biochemical parameters according to 1-year GFR change (∆eGFR) and 4-year 
composite clinical outcome
Data are shown as mean ± SD or median [interquartile range]
hs-CRP high-sensitive C reactive protein, MDA malondialdehyde
a Statistically significant intergroup differences are marked in bold
Characteristic 1-year eGFR changes (∆eGFR) P Progression to dialysis or death within 
4 years
P
< Median > Median Progressors Non-progressors
Age (years) 67 ± 11 59 ± 17 NS 67 ± 10 60 ± 16 NS
Hypertension n (%) 19 (95%) 17 (85%) NS 12 (80%) 24 (96%) NS
Diabetes n (%) 7 (21%) 7 (21%) NS 5 (33%) 9 (36%) NS
eGFR (mL/min/1.73 m2) 29 ± 19 37 ± 28 NS 25 ± 18 38 ± 24 0.08
∆eGFR (mL/min/1.73 m2) − 4.3 ± 2.5 8.7 ± 11.4 < 0.001a − 1.8 ± 5.3 5.2 ± 11.9 0.04a
BMI (kg/m2) 28.7 ± 3.8 27.7 ± 3.6 NS 28.1 ± 2.7 28.4 ± 3.9 NS
Hemoglobin (g/dL) 12.0 ± 2.1 13.4 ± 1.8 NS 11.7 ± 2.0 13.2 ± 1.9 NS
LDL-cholesterol (mM) 2.2 ± 0.7 2.4 ± 0.8 NS 2.3 ± 0.7 2.4 ± 0.6 NS
HDL-cholesterol (mM) 1.2 ± 0.3 1.3 ± 0.3 NS 1.2 ± 0.2 1.4 ± 0.3 NS
Triglycerides (mM) 1.5 ± 0.5 1.7 ± 0.5 NS 1.6 ± 0.6 1.6 ± 0.5 NS
hs-CRP (mg)/L 3.8 [1.6–5.9] 2.9 [0.9–5.4] NS 4.5 [1.6–5.4] 2.9 [0.9–5.1] NS
Calcium (mM) 2.2 ± 0.2 2.4 ± 0.2 NS 2.2 ± 0.3 2.3 ± 0.1 NS
Phosphate (mM) 1.1 ± 0.2 1.2 ± 0.2 NS 1.2 ± 0.2 1.1 ± 0.2 NS
Osteoprotegerin (μg/L) 2.7 [2.5–3.0] 2.1 [1.6–3.5] 0.07 3.0 [2.5–3.9] 1.9 [1.6–2.7] 0.002a
Arg (μM) 245 [178–408] 294 [274–396] NS 352 [260–521] 278 [210–299] 0.06
ADMA (μM) 0.63 [0.58–0.75] 0.60 [0.54–0.74] NS 0.73 [0.61–0.78] 0.60 [0.55–0.64] 0.08
Arg/ADMA ratio 388 [262–626] 517 [424–655] NS 468 [293–706] 448 [337–609] NS
hArg (μM) 0.99 [0.67–1.46] 1.19 [0.62–2.05] NS 0.97 [0.67–1.29] 1.34 [0.60–1.93] NS
Arg/hArg ratio 261 [144–429] 280 [150–483] NS 344 [248–595] 204 [121–422] 0.06
hArg/ADMA ratio 1.82 [1.19–2.28] 1.60 [1.17–3.30] NS 1.31 [1.09–1.76] 2.28 [1.30–3.15] 0.025a
Nitrite (μM) 2.47 [2.12–2.86] 2.40 [2.12–2.74] NS 2.52 [2.20–2.76] 2.40 [2.07–2.98] NS
Nitrate (μM) 83 [58–119] 87 [66–115] NS 72 [57–108] 87 [68–118] NS
MDA (μM) 1.40 [0.96–1.59] 0.93 [0.74–1.39] NS 1.11 [0.92–3.01] 1.05 [0.70–1.58] NS
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with relevant abnormalities in routine blood assays or with 
prehospital evidence of unstable creatinine levels were 
excluded. All patients were on a standard medical therapy 
recommended by practice guidelines, including low-dose 
aspirin, statins and angiotensin-converting enzyme inhibi-
tors for at least 3 months prior to the index hospitalization. 
CKD diagnosis was based on an eGFR value between 15 and 
59 mL/min/1.73 m2 by the CKD-EPI formula, corresponding 
to eGFR stages G3–G4 according to 2011 KDIGO classifi-
cation of CKD (Levey et al. 2011).
Follow-up data were collected during routine control vis-
its in our outpatient clinic, including control creatinine assay 
performed 12 ± 1 months after discharge. Patients or their 
relatives were contacted by telephone for the occurrence of 
a 4-year composite adverse clinical outcome, i.e., combined 
progression to dialysis or death from a CV cause, which was 
then confirmed by the review of medical records.
The study was approved by the Bioethics Commit-
tee of the Jagiellonian University (ethical approval No. 
KBET/364/B/2012) in adherence to the Declaration of Hel-
sinki. All participants provided written informed consent.
Biochemical analyses
OPG, hArg, ADMA and other biomarkers were measured in 
available EDTA plasma samples (n = 36, 35 and 32 for OPG, 
hArg and ADMA, respectively). OPG was measured by an 
enzyme immunoassay (R&D Systems, Minneapolis, MN, 
USA). LDL and HDL cholesterol, triglycerides, hemoglobin, 
creatinine and high-sensitive C-reactive protein (hs-CRP) 
were determined by standard clinical chemistry laboratory 
assays. Amino acids, malondialdehyde (MDA), nitrite and 
nitrate were analyzed by fully validated gas chromatography-
mass spectrometry (GC–MS) methods as described previ-
ously (Tsikas 2017; Hanff et al. 2017, 2019).
Statistical analysis
Data are presented as mean ± SD, median [interquartile 
range: 25th–75th percentile] or numbers and percentages. 
Normality was evaluated by Shapiro–Wilk’s test. Patients’ 
characteristics were compared according to the 1-year eGFR 
change (∆eGFR), dichotomized with the reference to the 
median value of − 0.9 mL/min/1.73 m2, or to a 4-year pro-
gression to dialysis or CV death. Intergroup differences in 
continuous data were estimated by two-tailed Student’s t 
test (or Welch’s t test in case of inhomogeneous variances 
assessed by Levene’s test) with prior decadic logarithmic 
 (log10) transformation; proportions were compared by Chi-
squared test. Bivariate Pearson’s correlation coefficients 
(rP) were calculated. Multiple logistic regression was used 
to estimate mutual independence of prognosticators with 
regard to the prediction of the progression to dialysis or 
the occurrence of CV death during a 4-year follow-up. 
Two-tailed P values < 0.05 were considered statistically 
significant.
Results
The concentrations of the biomarkers measured in the 
plasma samples of the study’s patients are summarized in 
Table 1. The relationships between OPG, hArg and ADMA 
are illustrated in Fig. 1.
Baseline plasma cocentrations of hArg and OPG cor-
related negatively with each other (rP = − 0.371, P = 0.03; 
Fig. 1a), which was maintained upon adjustment for eGFR. 
In contrast, baseline ADMA and OPG levels were posi-
tively correlated (rP = 0.385, P = 0.03; Fig. 1b). The hArg/
ADMA molar ratio correlated inversely with plasma OPG 
(rP = − 0.46, P = 0.009; Fig. 1c). ADMA and hArg concen-
trations were unrelated (rP = − 0.243, P = 0.187).
Six patients progressed to dialysis and nine died from 
CV causes over the subsequent 4 years. In these 15 patients 
(progressors), plasma OPG concentration was higher (3.0 
[2.5–3.9] vs. 1.9 [1.6–2.7] μg/L, P = 0.002) and the hArg/
ADMA molar ratio was lower (1.31 [1.09–1.76] vs. 2.28 
[1.30–3.15], P = 0.025) compared to the remainder (non-
progressors) (Table 1). Neither hArg nor ADMA plasma 
concentrations differed statistically significantly between 
progressors and non-progressors (Table 1). One-year eGFR 
decline was more pronounced in patients who developed 
future CV or renal endpoints (P = 0.04) (Table 1).
Multiple logistic regression revealed that higher OPG 
concentrations and lower hArg/ADMA ratios independently 
predicted 4-year composite CV and renal endpoints. Mean 
adjusted odds ratio for the adverse outcome was 1.30 [95% 
confidence interval, 1.03–1.64] (P = 0.02) per 1-μg/L incre-
ment in OPG and 0.3 [0.1–0.9] (P = 0.03) per 1-unit increase 
in the hArg/ADMA molar ratio (Hosmer–Lemeshow good-
ness-of-fit test, P = 0.3).
Discussion
To the best of our knowledge, a relationship between hArg 
and OPG has not been reported so far. Thus, our small study 
supplements previous observations of a positive correlation 
of OPG and ADMA in CAD (Morisawa et al. 2015) and 
essential hypertension (Tsioufis et al. 2011).
The patients’ plasma OPG concentrations were within 
reported ranges (Bjerre et al. 2014; Lewis et al. 2014), 
hArg levels were lower compared to healthy men or 
women (Kayacelebi et al. 2014a, b; Atzler et al. 2016), 
while ADMA was higher than in CAD patients (Thum 
et al. 2005). The hArg/ADMA molar ratio was lower in our 
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study group versus healthy subjects (Tsikas and Kayacel-
ebi 2014). Plasma nitric oxide (NO) metabolites nitrite and 
nitrate and the lipid peroxidation biomarker MDA were 
within references ranges reported previously (Hanff et al. 
2017; Tsikas 2017). As ADMA and hArg are formed from 
Arg in distinctly different pathways involving PRMT1 and 
AGAT, respectively, our observations suggest diminished 
AGAT activity, elevated PRMT1 activity, unaltered NOS 
activity and lipid peroxidation in our patients.
Given that elevated OPG, higher ADMA and lower hArg 
are established risk factors for renal and CV morbidity and 
mortality, it may suggest their synergistic contribution to the 
risk in patients with CKD and coexistent CAD via different 
detrimental pathways in the kidney and the vasculature. That 
high OPG and low hArg/ADMA molar ratio independently 
predicted the composite adverse clinical outcome and their 
mutual relationship was maintained upon adjustment for 
eGFR suggests that these prognostic effects were not entirely 
due to the association of abnormal levels of the biomark-
ers with impaired renal function (Fliser et al. 2005; Ravani 
et al. 2005, 2013; März et al. 2010; Røysland et al. 2012; 
Drechsler et al. 2013; Lewis et al. 2014).
Thus, high OPG and low hArg/ADMA ratio, albeit 
interrelated, appear to independently contribute to adverse 
clinical outcome. Admittedly, the underlying mechanisms 
connecting OPG with hArg and ADMA are still unresolved 
owing to their multiple, as yet not fully elucidated biologi-
cal actions. The intriguing findings of our small preliminary 
study warrant further validation in large cohorts.
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